Some other promising study results demonstrated that the addition of cytotoxic therapy to ADI-PEG20 led to an modest doubling of the response rate in ASS1-deficient malignant tumours.20–22 The enrolled patients in those studies were primarily chemotherapy naïve and thus more likely to benefit from the cancer treatment. The gene discussed is ASS1; the disease is cancer.